Slingshot members are tracking this event:

Celgene (CELG) Expects Phase 3 RADIANCE Confirmatory Trial Data in Q2 Evaluating Oral Ozanimod in Patients with Relapsing Multiple Sclerosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
May 22, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Confirmatory Trial, Ozanimod, Oral, Relapsing Multiple Sclerosis, Radiance